Drug Profile

Estriol/trimegestone vaginal ring - Evestra

Alternative Names: EVE 116

Latest Information Update: 19 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Evestra
Class Estrenes; Hormonal replacements; Norpregnadienes; Osteoporosis therapies
Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

19 Mar 2021 Phase-II development is ongoing for Pregnancy (Prevention, In volunteers) in Germany (Evestra pipeline, September 2020)
24 Feb 2020 Evestra completes phase II clinical trials in Pregnancy (Prevention, In volunteers) in Germany (Vaginal) (EudraCT2017-004664-36)
28 Jun 2018 Estriol/trimegestone vaginal ring - Evestra is available for licensing as of 28 Jun 2018. http://www.evestra.com/index.htm

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com